| Literature DB >> 30955884 |
Nikki K Lytle1, L Paige Ferguson1, Nirakar Rajbhandari1, Kathryn Gilroy2, Raymond G Fox1, Anagha Deshpande3, Christian M Schürch4, Michael Hamilton1, Neil Robertson2, Wei Lin5, Pawan Noel5, Martin Wartenberg6, Inti Zlobec6, Micha Eichmann6, José A Galván6, Eva Karamitopoulou6, Tami Gilderman1, Lourdes Adriana Esparza1, Yutaka Shima1, Philipp Spahn7, Randall French8, Nathan E Lewis7, Kathleen M Fisch9, Roman Sasik9, Sara Brin Rosenthal9, Marcie Kritzik1, Daniel Von Hoff5, Haiyong Han5, Trey Ideker10, Aniruddha J Deshpande3, Andrew M Lowy11, Peter D Adams12, Tannishtha Reya13.
Abstract
Drug resistance and relapse remain key challenges in pancreatic cancer. Here, we have used RNA sequencing (RNA-seq), chromatin immunoprecipitation (ChIP)-seq, and genome-wide CRISPR analysis to map the molecular dependencies of pancreatic cancer stem cells, highly therapy-resistant cells that preferentially drive tumorigenesis and progression. This integrated genomic approach revealed an unexpected utilization of immuno-regulatory signals by pancreatic cancer epithelial cells. In particular, the nuclear hormone receptor retinoic-acid-receptor-related orphan receptor gamma (RORγ), known to drive inflammation and T cell differentiation, was upregulated during pancreatic cancer progression, and its genetic or pharmacologic inhibition led to a striking defect in pancreatic cancer growth and a marked improvement in survival. Further, a large-scale retrospective analysis in patients revealed that RORγ expression may predict pancreatic cancer aggressiveness, as it positively correlated with advanced disease and metastasis. Collectively, these data identify an orthogonal co-option of immuno-regulatory signals by pancreatic cancer stem cells, suggesting that autoimmune drugs should be evaluated as novel treatment strategies for pancreatic cancer patients.Entities:
Keywords: Msi; Musashi; PDAC; RORg; cancer; cancer stem cells; cytokines; immune; pancreatic cancer; stem cells
Mesh:
Substances:
Year: 2019 PMID: 30955884 PMCID: PMC6711371 DOI: 10.1016/j.cell.2019.03.010
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582